BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29112457)

  • 1. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
    Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
    Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor of Differentiation-1 Sustains Mutant
    Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
    Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.
    Vallejo A; Perurena N; Guruceaga E; Mazur PK; Martinez-Canarias S; Zandueta C; Valencia K; Arricibita A; Gwinn D; Sayles LC; Chuang CH; Guembe L; Bailey P; Chang DK; Biankin A; Ponz-Sarvise M; Andersen JB; Khatri P; Bozec A; Sweet-Cordero EA; Sage J; Lecanda F; Vicent S
    Nat Commun; 2017 Feb; 8():14294. PubMed ID: 28220783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous
    Meder L; Florin A; Ozretić L; Nill M; Koker M; Meemboor S; Radtke F; Diehl L; Ullrich RT; Odenthal M; Büttner R; Heukamp LC
    Pathol Oncol Res; 2021; 27():596522. PubMed ID: 34257546
    [No Abstract]   [Full Text] [Related]  

  • 5. The ERBB network facilitates KRAS-driven lung tumorigenesis.
    Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
    Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YTHDF1 Promotes Cyclin B1 Translation through m
    Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of FOSL1 silencing on osteosarcoma cell proliferation, invasion and migration through the ERK/AP-1 signaling pathway.
    Han Y; Zhao X; Sun Y; Sui Y; Liu J
    J Cell Physiol; 2019 Apr; 234(4):3598-3612. PubMed ID: 30471098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IκB Kinase α Is Required for Development and Progression of
    Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
    Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLCγ1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia.
    Saliakoura M; Rossi Sebastiano M; Pozzato C; Heidel FH; Schnöder TM; Savic Prince S; Bubendorf L; Pinton P; A Schmid R; Baumgartner J; Freigang S; Berezowska SA; Rimessi A; Konstantinidou G
    Nat Cell Biol; 2020 Nov; 22(11):1382-1395. PubMed ID: 33077911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
    Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
    Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
    Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
    Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
    Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
    Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of PPARγ in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFβ1.
    Sippel TR; Johnson AM; Li HY; Hanson D; Nguyen TT; Bullock BL; Poczobutt JM; Kwak JW; Kleczko EK; Weiser-Evans MC; Nemenoff RA
    Mol Cancer Res; 2019 Aug; 17(8):1748-1758. PubMed ID: 31088909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
    Wang IC; Ustiyan V; Zhang Y; Cai Y; Kalin TV; Kalinichenko VV
    Oncogene; 2014 Nov; 33(46):5391-6. PubMed ID: 24213573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 promotes Kras-dependent lung adenocarcinoma.
    Zhao P; Damerow MS; Stern P; Liu AH; Sweet-Cordero A; Siziopikou K; Neilson JR; Sharp PA; Cheng C
    Oncogene; 2013 Oct; 32(43):5186-90. PubMed ID: 23208496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.
    Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Yamada G; Hasegawa T; Miyagi Y; Niki T; Watanabe A; Takahashi H; Sakuma Y
    Int J Oncol; 2018 Jul; 53(1):33-46. PubMed ID: 29658609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice.
    Rosenfeld YB; Krumbein M; Yeffet A; Schiffmann N; Mishalian I; Pikarsky E; Oberman F; Fridlender Z; Yisraeli JK
    Oncogene; 2019 May; 38(21):4169-4181. PubMed ID: 30700831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.